Clinical Trials Using PI3K-delta Inhibitor TGR-1202

Clinical trials are research studies that involve people. The clinical trials on this list are studying PI3K-delta Inhibitor TGR-1202. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-15 of 15
  • Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

    This phase II trial studies how well obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with obinutuzumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, prednisone, and bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy will work better in treating patients with grade I-IIIa follicular lymphoma.
    Location: 386 locations

  • Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

    Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
    Location: 20 locations

  • Study to Assess the Efficacy and Safety of Ublituximab Plus Umbralisib in Combination With Venetoclax in Subjects With CLL

    ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)
    Location: 7 locations

  • Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

    Phase 2, two cohort trial evaluating the addition of ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in subjects with Chronic Lymphocytic Leukemia (CLL), who are currently on treatment with ibrutinib, alacabrutinib or venetoclax.
    Location: 3 locations

  • Umbralisib and Rituximab as Initial Therapy for Follicular Lymphoma and Marginal Zone Lymphoma

    This phase II trial studies how well umbralisib and rituximab work as initial therapy for patients with follicular lymphoma and marginal zone lymphoma. Umbralisib blocks a protein called P13K, that plays a role in the way cells grow. In follicular lymphoma and marginal zone lymphoma, P13K is increased and more active than usual, allowing cancer cells to grow and survive. Umbralisib may kill cancer cells in some patients and cause their tumors to shrink. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Umbralisib and rituximab combination may work better than standard initial therapies in patients with follicular lymphoma and marginal zone lymphoma.
    Location: 2 locations

  • Phase I / II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL / SLL and NHL

    Phase I / II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL / SLL and NHL
    Location: 2 locations

  • Pembrolizumab and Umbralisib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma

    This phase I trial studies side effects and best dose of pembrolizumab and umbralisib in treating patients with chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma that have come back or do not respond to treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and umbralisib may work better in treating patients with chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma.
    Location: 3 locations

  • Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated, Relapsed, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trial studies the effect of acalabrutinib, umbralisib, and ublituximab in treating chronic lymphocytic leukemia or small lymphocytic lymphoma that is previously untreated, has come back (relapsed), or has not responded to treatment (refractory). Acalabrutinib is a type of drug called a kinase inhibitor. It blocks a type of protein called Bruton tyrosine kinase (BTK) that helps chronic lymphocytic leukemia cells live and grow. By blocking BTK, acalabrutinib may kill cancer cells or stop them from growing. Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. Early clinical trials have shown that umbralisib can kill cancer cells in some patients and cause their tumors to shrink. Ublituximab is a type of investigational drug called a monoclonal antibody. A monoclonal antibody is a type of protein made in the laboratory that can locate and bind to substances in the body, including tumor cells. By binding to the tumor cells, the antibody might prevent the tumor cell from growing and spreading. Giving acalabrutinib, umbralisib, and ublituximab may work better in controlling cancer growth in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Location: Dana-Farber Cancer Institute, Boston, Massachusetts

  • Ublituximab and Umbralisib for the Treatment of Treatment-Naive Follicular or Marginal Zone Lymphoma

    This phase II trial studies the effect of ublituximab and umbralisib in treating patients with treatment-naive follicular or marginal zone lymphoma. Ublituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving ublituximab and umbralisib may help treat patients with follicular or marginal zone lymphoma.
    Location: University of Colorado Hospital, Aurora, Colorado

  • Umbralisib for the Treatment of Treatment Naive Chronic Lymphocytic Leukemia

    This phase II trial studies how well umbralisib works in treating patients with chronic lymphocytic leukemia that has not been previously treated (treatment naive). Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Carfilzomib and Umbralisib in Treating Patients with Relapsed or Refractory Lymphoma

    This phase Ib trial studies the best dose and side effects of carfilzomib and umbralisib and how well they work in treating patients with lymphoma that has come back or does not respond to treatment. Carfilzomib and umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

    This is a multi-center, open-label, study to evaluate the safety and efficacy of ublituximab (TG-1101) in combination with TGR-1202 for patients who have progressed on treatment arms previously enrolled in Protocol UTX-TGR-304
    Location: 11 locations

  • Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and / or TGR-1202 Trials

    This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and / or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
    Location: University of Nebraska Medical Center, Omaha, Nebraska

  • Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

    This phase I trial studies the side effects and best dose of lenalidomide and umbralisib when given together with ublituximab in treating patients with non-Hodgkin lymphoma or mantle cell lymphoma that tends to grow and spread slowly (indolent) and has come back (relapsed) or does not respond to treatment (refractory). Lenalidomide may stop or slow non-Hodgkin lymphoma or mantle cell lymphoma by blocking the growth of new blood vessels necessary for tumor growth. Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Ublituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. This trial is being done to evaluate the safety of lenalidomide, umbralisib, and ublituximab in treating non-Hodgkin lymphoma or mantle cell lymphoma.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Umbralisib and Pembrolizumab in Treating Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

    This phase II trial studies how well umbralisib and pembrolizumab work in treating patients with classical Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving umbralisib and pembrolizumab may work better in treating classical Hodgkin lymphoma.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington